Quick Answer
Aligos Therapeutics, Inc. reported Stockholders Equity of $53.55 million for the year ending 2025.
- Aligos Therapeutics, Inc. showed an increase of +284.8% in Stockholders Equity from 2024 to 2025.
- This data is from Aligos Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2019: -$33.37 million | Q3 2019: -$47.02 million | Q1 2020: -$83.94 million | Q2 2020: -$104.57 million | Q3 2020: -$136.67 million | Q1 2021: $195.22 million | Q2 2021: $168.88 million | Q3 2021: $217.01 million | Q1 2022: $152.89 million | Q2 2022: $136.98 million | Q3 2022: $122.01 million | Q1 2023: $84.75 million | Q2 2023: $69.64 million | Q3 2023: $54.82 million | Q1 2024: $59.80 million | Q2 2024: $67.23 million | Q3 2024: $50.10 million | Q1 2025: $116.45 million | Q2 2025: $101.87 million | Q3 2025: $71.83 million.
- Over the full 8 years of available data (2018 to 2025), Aligos Therapeutics, Inc.'s Stockholders Equity has grown by 489.5%.
- Historical annual values: Fiscal year 2025: $53.55 million | Fiscal year 2024: -$28.97 million | Fiscal year 2023: $92.08 million | Fiscal year 2022: $103.90 million | Fiscal year 2021: $184.73 million | Fiscal year 2020: $220.04 million | Fiscal year 2019: -$64.89 million | Fiscal year 2018: -$13.75 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: